Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Novavax Inc. closed 61.37% short of its 52-week high of $17.81, which the company reached on July 26th.

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

Novavax (NVAX) closed the most recent trading day at $6.97, moving +1.9% from the previous trading session. The stock's change was more than the S&P 500's daily gain of 0.14%. On the other hand, the ...

Novavax Inc. closed 60.92% short of its 52-week high of $17.81, which the company reached on July 26th.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

NVAX stock reached a 52-week high of $331.68 a share on February 8th. It then fell 54% before rebounding and climbing 70% higher. However, after peaking at $257.67 on April 27, ...

When the race to develop a Covid-19 vaccine began in early 2020, Novavax stock (NASDAQ: NVAX) was viewed as one of the front runners, with the company securing the largest funding from the U.S ...